Nano Dimension Ltd.
5.20%
10,942,087
1643303
63008G203
Feb 16, 2026
Feb 19, 2026, 09:50 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | CO | 5.20% | 10,942,087 | 0 | 10,942,087 |
Disclosure Items (6)
Ordinary Shares, par value NIS 5.00 per share
Nano Dimension Ltd.
60 TOWER ROAD, WALTHAM, MA, 02451
Item 2(a) is hereby amended and restated in its entirety as follows: This Schedule 13D (this "Schedule 13D" or this "Statement") is being filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended (the "Act"), by and on behalf of Oramed Pharmaceuticals Inc., a Delaware corporation (the "Reporting Person"). The Reporting Person declares that neither the filing of this Statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any of the securities covered by this Statement.
Item 2(b) is hereby amended and restated in its entirety as follows: The business address of the Reporting Person is 1185 Avenue of the Americas, 3rd Floor, New York, NY, 10036.
Item 2(c) is hereby amended and restated in its entirety as follows: The Reporting Person is engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins.
Item 2(e) is hereby amended and restated in its entirety as follows: During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 2(f) is hereby amended and restated in its entirety as follows: The Reporting Person is organized under the laws of the State of Delaware.
Item 3 is hereby amended and supplemented as follows: "In open market purchases on February 17, 2026 and February 18, 2026, the Reporting Person expended an aggregate of approximately $2,800,500 (excluding commissions) to acquire an aggregate of 1,425,000 Ordinary Shares in various open market transactions. The funds used for the purchase of the Ordinary Shares reported in this Schedule 13D were derived from the general working capital of the Reporting Person."
Item 5(a) is hereby amended and restated in its entirety as follows: "(a) The percentage reported in Item 13 on the cover pages hereto is based upon 210,334,767 Ordinary Shares of the Issuer outstanding as of October 14, 2025, according to the Report on Form 6-K for the month of December 2025, filed by the Issuer with the U.S. Securities and Exchange Commission (the "SEC") on December 4, 2025."
Item 5(c) is hereby amended and restated in its entirety as follows: "(c) Other than as set forth on Annex A of this Schedule 13D, there have been no transactions in the class of securities reported on that were effected by the Reporting Persons during the past sixty days or since the most recent filing of Schedule 13D, whichever is less."
Item 6 is hereby amended and supplemented as follows: "The information set forth in Item 4 of this Schedule 13D is hereby incorporated herein by reference."